SLC22A17 and cutaneous mastocytosis: To the best of our knowledge, the reported findings demonstrate for the first time that hypermethylation of the SLC22A17 promoter hotspot may represent not only a promising epigenetic hallmark of cancer initiation but also a putative methDNA-based biomarker to predict worse prognosis for CM patients.